apl. Prof. Dr. Lucie Heinzerling



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Serio - Side Effect Registry in Immuno-Oncology (2020) Koutzamanidis R, Mentzer D, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel-Becker S, Pavel ME, et al. Conference contribution The role of immune checkpoint blockade in uveal melanoma (2020) Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M, Berking C, Heppt M Journal article, Review article Skin Cancer in Childhood and Adolescents: Treatment and Implications for the Long-Term Follow-Up (2020) Heinzerling L, Eigentler TK Authored book Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) (2020) Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, et al. Journal article Four cases of erysipelas-like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors (2020) Pföhler C, Hassel JC, Heinzerling L, Müller CS Journal article Monitoring skin metastases during immuno- and targeted therapy using total-body 3D photography (2020) Erdmann M, Heinzerling L, Schuler G, Berking C, Schliep S Journal article Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease (2020) Weiß J, Kirchberger M, Heinzerling L Journal article Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al. Journal article, Review article Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study (2019) Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, et al. Journal article A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution